ACTIVE
Financiado
Articular Cartilage Treatment with Injectable hydrogel is Valuable and long-term...
Hy2Care brings a regenerative Injectable Hydrogel, of joint- and cartilage-mimicking composition, that is used to treat damaged cartilage. The cartilage defects are easily filled with a syringe during a standard one time arthrosco...
Hy2Care brings a regenerative Injectable Hydrogel, of joint- and cartilage-mimicking composition, that is used to treat damaged cartilage. The cartilage defects are easily filled with a syringe during a standard one time arthroscopy. The hydrogel fill the defect, prevents ingrowth of scar tissue and allows the body to heal itself by creating true Hyaline cartilage, ensuring an optimal regenerated tissue. The high-quality regeneration provides the basis for a long lasting repair, postponing or even preventing the onset of osteoarthritis.
The gel binds covalently to the surrounding cartilage ensuring integration of the new tissue. Revalidation is fast as the cartilage regrowth follows the degradation of the gel. The lasting repair not only prevents additional secondary treatments but also pain, disability and escalating follow-on costs.
In submission of the last cut off of the EIC in october 2020 Hy2Care scored a 14.0 and recieved the seal of excellence.
ver más
Duración del proyecto: 22 meses
Fecha Inicio: 2022-11-11
Fecha Fin: 2024-09-30
Fecha Fin: 2024-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-ACCELERATOROPEN-01:
EIC Accelerator Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
HY2CARE BV
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5